The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/10000 - 1/50000. Detects a band of approximately 45, 56, 120 kDa (predicted molecular weight: 48, 72 kDa).
1/10 - 1/100.
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Heat up to 98 degrees C, below boiling, and then let cool for 10-20 min
Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
Sequence similaritiesContains 3 cystatin domains.
Post-translational modificationsBradykinin is released from kininogen by plasma kallikrein. Hydroxylation of Pro-383 occurs prior to the release of bradykinin. Phosphorylation sites are present in the extracelllular medium. N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
Western blot - Anti-Kininogen 1 antibody [EPR6097] (ab124737)
All lanes : Anti-Kininogen 1 antibody [EPR6097] (ab124737) at 1/10000 dilution
Lane 1 : Human plasma lysate Lane 2 : Human platelet lysate Lane 3 : Human ovarian cancer lysates
Lysates/proteins at 10 µg per lane.
Secondary Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size : 48, 72 kDa ab124737 is detecting three isoforms of Kininogen 1: full length (120 kDa), light chain (56 kDa), and cleavage form (45 kDa).
References for Anti-Kininogen 1 antibody [EPR6097] (ab124737)
This product has been referenced in:
Schrödter S et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Mol Cancer15:10 (2016).
Read more (PubMed: 26831905) »
Yao Y et al. Screening and identification of potential predictive biomarkers for Down's syndrome from second trimester maternal serum. Expert Rev Proteomics12:97-107 (2015).
Read more (PubMed: 25434962) »